Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

FDA Grants Accelerated Approval to Repotrectinib for NTRK+ Solid Tumors

June 13th 2024

The FDA granted accelerated approval to repotrectinib (Augtyro) for select patients with solid tumors harboring a NTRK gene fusion.

FDA Grants Full Approval to Selpercatinib for RET+ Thyroid Cancer

June 12th 2024

The FDA granted full approval to selpercatinib for select patients with advanced or metastatic RET fusion–positive thyroid cancer.

Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC

June 10th 2024

The European Commission has approved alectinib for adjuvant use in adult patients with ALK+ non–small cell lung cancer at high risk of recurrence.

A Geneticist and PCP Detail Considerations With New Screening Recommendations for Breast Cancer

June 5th 2024

Brittany L. Bychkovsky, MD, MSc, and Lydia Pace, MD, MPH, explain approaches to breast cancer screening and considerations with the final USPSTF screening recommendations.

OncLive’s May Roundup of Key FDA Approvals in Oncology

May 31st 2024

Here is your guide to important regulatory approvals made by the FDA in May 2024.

FDA Grants Accelerated Approval to Selpercatinib for Pediatric RET+ Metastatic Thyroid Cancer or Solid Tumors

May 29th 2024

The FDA has granted accelerated approval to selpercatinib for pediatric patients with select RET-altered metastatic thyroid cancers or solid tumors.

AFM24 Plus Atezolizumab Wins FDA Fast Track Designation for EGFR Wild-Type NSCLC

May 29th 2024

The FDA granted fast track designation AFM24 plus atezolizumab for advanced EGFR wild-type non–small cell lung cancer.

Tovorafenib Offers an Efficacious Option for R/R BRAF-Positive Pediatric Low-Grade Glioma

May 28th 2024

Sarah ES Leary, MD, MS, details the significance of the FDA-approval of tovorafenib for patients with relapsed or refractory BRAF-positive pediatric low-grade glioma.

Narayan Discusses Bladder Preservation and the Role of Gene Therapies in NMIBC

May 23rd 2024

Vikram M. Narayan, MD, highlights takeaways from 5-year follow-up data examining the gene therapy nadofaragene firadenovec and details promising emerging therapies for bladder cancer.

Guardant360 CDx Gains European Union Certification for Tumor Profiling in Solid Tumors

May 22nd 2024

Guardant360 CDx received In Vitro Diagnostic Regulation certification for tumor mutation profiling in solid tumors and for companion diagnostic indications in NSCLC and breast cancer.

Precision Cancer Care: Preserving Normal Tissue With Proton Therapy

May 20th 2024

Radiation therapy is a critical component of cancer care that is currently being used in approximately 50% of all patients with cancer.

Revisit Every OncLive On Air Episode From April 2024

May 13th 2024

In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.

CX-904 Generates a Favorable Safety Profile in Phase 1 Trial of EGFR-Expressing Solid Tumors

May 9th 2024

The T-cell engager CX-904 had a favorable safety profile when administered as monotherapy in patients with advanced or metastatic solid tumors.

Efficacy With NRG1-Directed Agents in NSCLC

May 6th 2024

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses clinical efficacy with agents targeted for NRG1-fusion–positive non–small cell lung cancer.

Acalabrutinib Yields Long-Term Efficacy in a Pooled Analysis of Higher-Risk CLL

May 6th 2024

Treatment with acalabrutinib-based regimens led to long-term benefits in patients with higher-risk CLL, across all lines of therapy.

Ongoing Research Efforts Targeting NRG1 in Lung Cancer

May 6th 2024

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses ongoing research for patients with non–small cell lung cancer who harbor NRG1 fusions.

Standard Treatments for NRG1 Fusion+ NSCLC

May 6th 2024

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses standard treatments for patients with non–small cell lung cancer who harbor NRG1 fusions.

Glecirasib Generates Durable Responses in Pretreated Advanced KRAS G12C+ NSCLC

April 30th 2024

Glecirasib elicited responses and demonstrated a manageable safety profile in patients with pretreated advanced NSCLC harboring KRAS G12C mutations.

Dr Ahluwalia on Advancements in the Management of Brain Metastases

April 30th 2024

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses how advancements in precision medicine have improved outcomes for patients with brain metastases.

Differences Between DNA and RNA Testing for NRG1

April 29th 2024

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses differences between DNA and RNA fusions for detecting NRG1 fusions.